Loading stock data…
RZLT
$3.90-0.18 (-4.41%)
After Hours$3.90+0.00 (+0.00%)· Last close Jun 9
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Rezolute, Inc. in the Healthcare sector is trading at $3.90. Wall Street consensus targets $7.11 (9 analysts), implying a +82.3% move over the next 12 months. The stock is currently 66% below its 52-week high of $11.46, remaining 26.6% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +82.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$3.90
Potential Downside
0%
Whystock Fair Value$3.90
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Buy
Mean target$7.11+82.3%
Range$4.00 – $14.00
Fundamentals
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-69.74%
Volume
Today's trading volume
2.21M
Recent News
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?
Rezolute rises 38% in a week after interim upLIFT data shows most tumor HI patients cut or eliminate IV glucose support.
Yum! Brands upgraded, Chipotle downgraded: Wall Street's top analyst calls
Yum! Brands upgraded, Chipotle downgraded: Wall Street's top analyst calls
Rezolute’s stock up on interim Phase III tumour HI data
Topline results for the fully enrolled open-label study are expected in the second half of 2026.
High Growth Tech Stocks in US for May 2026
Over the last 7 days, the United States market has remained flat, yet it is up 25% over the past year with earnings expected to grow by 17% annually in the coming years. In this context of robust growth and stability, identifying high-growth tech stocks involves focusing on companies that demonstrate strong innovation capabilities and adaptability to evolving market demands.
Stock Market Today, April 6: Soleno Therapeutics Climbs After $2.9 Billion All-Cash Buyout Agreement
Neurocrine’s rare-disease push, anchored by Soleno’s VYKAT XR, reshapes biotech dealmaking focus, today, April 6, 2026.